2019 CYIR Finalized
48 Comments 1. These findings, while ostensibly suggesting that e-cigarettes may have a role in the smoking cessation armamentarium, cre- ate a troubling “third way” in which combustible cigarette use is eliminated but ongoing nicotine dependence is enabled. 2. The smoking cessation rates in the NRT group at 26 weeks was much higher than reported in prior NRT trials making one question whether the cohort was representative of motivated smokers targeted in prior studies. 3. The open-label structure invites concerns about the con- founding of quit attempts by perceived novelty or prior failed attempts with NRT (not ascertained). 4. The public health consequences of adult e-cigarette use are substantial given the epidemic of youth uptake with a strong footprint of products with extremely high nicotine content. 5. The trial data need to be weighed against the contemporane- ous epidemic that has led to very high nicotine dependence among adolescents and teenagers. IMPLEMENTATION OF TOBACCO DEPENDENCE TREATMENT Bernstein SL, Weiss J, Dewitt M, Tetrault JM, Hsiao AL, Dziura J, Sussman S, Miller T, Carpenter K, O’Connor P, Toll B. A randomized trial of decision support for tobacco dependence treatment in an inpatient electronic medi- cal record: clinical results. Implementation Science 2019. 14(1):8. Summary The initiation of tobacco dependence treatment in an inpatient setting takes advantage of what is generally considered a “teachable moment” since hospitals are smoke-free environments and the term of stay can be construed as a quit attempt. This single hospital system study randomized an EMR-embedded alert with a decision support tool and order set to 254 physicians who admitted patients self-designated as current smokers. The order set prescribed tobacco treatment medications, made a refer- ral to a quitline, populated the problem list with “Tobacco Use Disorder,” and sent a secure message to the primary care physician about the study. The control arm received an alert but no decision support tool and order set. The patients were followed up at 1, 6, and 12 months with biochemical confirmation on all asserting abstinence at 12 months. The alert was fired for 10,339 patients (5391 with intervention physicians and 5548 with control physicians). Compared to control physicians, intervention physicians were more likely to order tobacco cessation medications, refer the patient to the quitline, populate the problem list with tobacco dependence designation, and message the primary care physician about the plan. A subgroup of 1044 enrollees were subjected to intensive follow-up for 1 year and showed 11.5% abstinence in the intervention arm and 11.7% abstinence in the control arm (p=0.94) controlling for age, sex, race, ethnicity, and SES. There were no differ- ences in abstinence at 1 month and 6 months. Comments 1. The current study created an automatic opt-out system that triggered a multicomponent intervention that did not require a tobacco treatment team and could be incorporated into a clini- cal workflow. 2. The lack of an effect on long-term abstinence is likely driven by the ease of availability of post-discharge medications and behavioral support. 3. Despite the recognition of hospitalization, especially for smok- ing related diseases, as a quit attempt and a “teachable moment,” the incorporation of inpatient tobacco dependence treatments have not resulted in long-term abstinence without discharge programs beyond quitlines. NEW SMOKING CESSATION TOOLS Hatsukami DK, Luo X, Jensen JA, alAbsi M, Allen SS, Carmella SG, Chen M, Cinciripini PM, Denlinger-Apte R, Drobes DJ, Koopmeiners JS, Lane T, Le CT, Leischow S, Luo K, McClernon J, Murphy SE, Paiano V, Robinson JD, Severson H, Sipe C, Strasser AA, Strayer LG, Tang MK, Vandrey R, Hecht SS, Benowitz NL, Donny EC. Effect of Immediate vs Gradual Reduction in Nicotine Content of Cigarettes on Biomarkers of Smoke Exposure. JAMA 2018. 320(9):880. Summary This study is a multicenter, double-blind, randomized, parallel-design trial of immediate vs. gradual reduction in nicotine content to very low levels over 22 weeks. Two weeks of baseline smoking was followed by 20 weeks of the intervention: immediate reduction to 0.4 mg of nicotine per gram of tobacco and gradual reduction from 15.5 mg to 0.4 mg per gram of tobacco with 5 monthly dose changes. The control group maintains conventional levels of nicotine in cigarettes, 15.5 mg per gram of tobacco. Smokers not ready to quit (N=1250) at 10 U.S. sites were randomized to the three groups with 988 completing the study. During the study, behavioral counseling was offered to those who expressed an interest in quitting. The primary endpoint was between-group differences in 3 co-primary biomarkers of smoke exposure (exhaled CO, urine 3-HPMA and urine PheT) employing ROC measurements. Significant reduc- tions in the triple toxicant readouts were observed in the immediate versus gradual reduction arms, specifically for CO (mean difference -4.06 ppm, [-4.89 - -3.23, p<0.0055]), 3-HPMA (ratio of geometric means 0.83, [0.77 – 0.88, p<0.0055]), Phe-T (ratio of geometric means 0.88 [0.83 – 0.93, p<0.0055]). Significant reductions were also observed in the immediate versus control group for all three toxicant measures. No differences were observed in the gradual versus control group for CO, 3-HPMA or Phe-T. Comments 1. The incorporation of low nicotine cigarettes into a smoking ces- sation program, especially for highly dependent smokers, has generated a great deal of interest among the tobacco control community and the FDA. TOBACCO DEPENDENCE
Made with FlippingBook
RkJQdWJsaXNoZXIy MTM1ODMw